BR112016015763B8 - preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma - Google Patents
preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesmaInfo
- Publication number
- BR112016015763B8 BR112016015763B8 BR112016015763A BR112016015763A BR112016015763B8 BR 112016015763 B8 BR112016015763 B8 BR 112016015763B8 BR 112016015763 A BR112016015763 A BR 112016015763A BR 112016015763 A BR112016015763 A BR 112016015763A BR 112016015763 B8 BR112016015763 B8 BR 112016015763B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical preparation
- pyridylaminocetic
- intraocular pressure
- glaucoma
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
preparação farmacêutica, e, método para tratamento ou prevenção de glaucoma ou hipertensão ocular o propósito da presente invenção é descobrir quais compostos dentre o vasto número de compostos de ácido piridilaminocético apresentam uma ação de abaixamento de pressão intraocular notoriamente superior e podem servir como um agente abaixador de pressão intraocular ou como um agente tera-pêutico ou preventivo contra glaucoma ou hipertensão ocular, e descobrir a maneira de administração e/ou de dosagem na qual os compostos desco-bertos concederão um efeito terapêutico ou profilático efetivo quando admi-nistrados aos pacientes (principalmente seres humanos). é fornecida uma preparação farmacêutica para abaixar a pressão intraocular ou para prevenir ou tratar glaucoma ou hipertensão intraocular, a dita preparação farmacêutica contendo 0,0003 a 0,01% (m/v) de (6-{[4-(pirazol-1-il)benzil](piridin-3-ilsulfonil)aminometil}piridin-2-ilamino)acetato de isopropila, ou um sal do mesmo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461925882P | 2014-01-10 | 2014-01-10 | |
US61/925882 | 2014-01-10 | ||
PCT/JP2015/050366 WO2015105144A1 (ja) | 2014-01-10 | 2015-01-08 | ピリジルアミノ酢酸化合物を含む医薬製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016015763B1 BR112016015763B1 (pt) | 2020-09-01 |
BR112016015763B8 true BR112016015763B8 (pt) | 2020-09-15 |
Family
ID=53520400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016015763A BR112016015763B8 (pt) | 2014-01-10 | 2015-01-08 | preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma |
Country Status (26)
Country | Link |
---|---|
US (8) | US9415038B2 (pt) |
EP (3) | EP3750541A1 (pt) |
JP (6) | JP5846338B2 (pt) |
KR (1) | KR101824829B1 (pt) |
CN (2) | CN108743587B (pt) |
AU (1) | AU2015205188B2 (pt) |
BR (1) | BR112016015763B8 (pt) |
CA (1) | CA2936026C (pt) |
CL (1) | CL2016001756A1 (pt) |
DK (1) | DK3093018T3 (pt) |
EA (1) | EA031734B1 (pt) |
ES (2) | ES2711091T3 (pt) |
GE (1) | GEP20186917B (pt) |
HK (1) | HK1223036A1 (pt) |
HU (1) | HUE041653T2 (pt) |
IL (1) | IL246447B (pt) |
MX (1) | MX370361B (pt) |
MY (1) | MY163235A (pt) |
PH (1) | PH12016501357A1 (pt) |
PL (1) | PL3093018T3 (pt) |
PT (1) | PT3093018T (pt) |
SG (1) | SG11201605653RA (pt) |
TR (1) | TR201902019T4 (pt) |
TW (1) | TWI598113B (pt) |
UA (1) | UA117506C2 (pt) |
WO (1) | WO2015105144A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101858373B1 (ko) * | 2014-01-10 | 2018-05-15 | 산텐 세이야꾸 가부시키가이샤 | 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물 |
EP3750541A1 (en) | 2014-01-10 | 2020-12-16 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
AU2015205179B2 (en) | 2014-01-10 | 2019-09-19 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition containing pyridylamino acetic acid compound |
MX2017007572A (es) * | 2014-12-12 | 2018-02-09 | Kowa Co | Composicion acuosa. |
AR105215A1 (es) * | 2015-07-01 | 2017-09-13 | Santen Pharmaceutical Co Ltd | Formulación de depósito que contiene ésteres de ácido cítrico |
JP7032134B2 (ja) * | 2015-07-09 | 2022-03-08 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する予防及び/又は治療剤 |
WO2018230713A1 (ja) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
WO2019065838A1 (ja) | 2017-09-29 | 2019-04-04 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する医薬 |
EP3730143A4 (en) | 2017-12-21 | 2021-08-18 | Santen Pharmaceutical Co., Ltd. | OMIDENEPAG COMBINATION |
US11666563B2 (en) | 2017-12-28 | 2023-06-06 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
WO2019209955A2 (en) * | 2018-04-24 | 2019-10-31 | Allergan, Inc. | Presbyopia treatments |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002356420A (ja) * | 2001-03-27 | 2002-12-13 | Santen Pharmaceut Co Ltd | 安定な水性液剤 |
DK2264009T3 (en) | 2008-03-12 | 2019-04-15 | Ube Industries | PYRIDYLAMINE ACEDIC ACID COMPOUND |
CA2757291C (en) * | 2009-03-30 | 2017-05-23 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of glaucoma |
JP2011057633A (ja) * | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | ピリジルアミノ酢酸化合物を含有する医薬 |
US20120202863A1 (en) * | 2011-02-03 | 2012-08-09 | Gerald Horn | Compositions and methods for treatment of glaucoma |
JP2014019650A (ja) * | 2012-07-13 | 2014-02-03 | Santen Pharmaceut Co Ltd | スルホンアミド化合物とタフルプロストの組み合わせ |
US9339496B2 (en) * | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
KR102074020B1 (ko) * | 2012-07-13 | 2020-02-05 | 산텐 세이야꾸 가부시키가이샤 | 술폰아미드 화합물의 조합 |
US20140018350A1 (en) | 2012-07-13 | 2014-01-16 | Asahi Glass Co., Ltd. | Combination of sulfonamide compound and tafluprost |
KR101858373B1 (ko) | 2014-01-10 | 2018-05-15 | 산텐 세이야꾸 가부시키가이샤 | 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물 |
EP3750541A1 (en) | 2014-01-10 | 2020-12-16 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
AU2015205179B2 (en) * | 2014-01-10 | 2019-09-19 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition containing pyridylamino acetic acid compound |
-
2015
- 2015-01-08 EP EP20183949.5A patent/EP3750541A1/en not_active Withdrawn
- 2015-01-08 BR BR112016015763A patent/BR112016015763B8/pt active IP Right Grant
- 2015-01-08 JP JP2015527691A patent/JP5846338B2/ja active Active
- 2015-01-08 UA UAA201607988A patent/UA117506C2/uk unknown
- 2015-01-08 AU AU2015205188A patent/AU2015205188B2/en active Active
- 2015-01-08 ES ES15735133T patent/ES2711091T3/es active Active
- 2015-01-08 EP EP15735133.9A patent/EP3093018B1/en active Active
- 2015-01-08 US US14/592,167 patent/US9415038B2/en active Active
- 2015-01-08 DK DK15735133.9T patent/DK3093018T3/en active
- 2015-01-08 EP EP18190494.7A patent/EP3424503B1/en active Active
- 2015-01-08 CN CN201811020654.5A patent/CN108743587B/zh active Active
- 2015-01-08 GE GEAP201514239A patent/GEP20186917B/en unknown
- 2015-01-08 EA EA201691402A patent/EA031734B1/ru unknown
- 2015-01-08 PT PT15735133T patent/PT3093018T/pt unknown
- 2015-01-08 SG SG11201605653RA patent/SG11201605653RA/en unknown
- 2015-01-08 KR KR1020167018735A patent/KR101824829B1/ko active IP Right Grant
- 2015-01-08 ES ES18190494T patent/ES2834334T3/es active Active
- 2015-01-08 MX MX2016009063A patent/MX370361B/es active IP Right Grant
- 2015-01-08 MY MYPI2016001271A patent/MY163235A/en unknown
- 2015-01-08 TW TW104100502A patent/TWI598113B/zh active
- 2015-01-08 PL PL15735133T patent/PL3093018T3/pl unknown
- 2015-01-08 TR TR2019/02019T patent/TR201902019T4/tr unknown
- 2015-01-08 WO PCT/JP2015/050366 patent/WO2015105144A1/ja active Application Filing
- 2015-01-08 CN CN201580003994.5A patent/CN105899209B/zh active Active
- 2015-01-08 CA CA2936026A patent/CA2936026C/en active Active
- 2015-01-08 HU HUE15735133A patent/HUE041653T2/hu unknown
- 2015-11-09 JP JP2015219845A patent/JP6491588B2/ja active Active
-
2016
- 2016-06-26 IL IL246447A patent/IL246447B/en active IP Right Grant
- 2016-07-08 PH PH12016501357A patent/PH12016501357A1/en unknown
- 2016-07-08 CL CL2016001756A patent/CL2016001756A1/es unknown
- 2016-07-18 US US15/212,592 patent/US9943510B2/en not_active Ceased
- 2016-09-29 HK HK16111395.0A patent/HK1223036A1/zh unknown
-
2018
- 2018-02-13 US US15/895,100 patent/US10179127B2/en active Active
- 2018-08-28 US US16/114,721 patent/USRE48183E1/en active Active
- 2018-12-06 US US16/211,839 patent/US10702511B2/en active Active
-
2019
- 2019-03-01 JP JP2019037654A patent/JP6785330B2/ja active Active
-
2020
- 2020-05-29 US US16/887,108 patent/US11197849B2/en active Active
- 2020-10-26 JP JP2020178844A patent/JP7087040B2/ja active Active
-
2021
- 2021-11-08 US US17/521,031 patent/US11793798B2/en active Active
-
2022
- 2022-06-08 JP JP2022092999A patent/JP7402922B2/ja active Active
-
2023
- 2023-09-11 US US18/464,646 patent/US20240000763A1/en active Pending
- 2023-12-11 JP JP2023208468A patent/JP2024019479A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016015763B8 (pt) | preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma | |
BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
BR112017017078A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença. | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112017017888A2 (pt) | derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
BR112016025997A8 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
BRPI0608152A2 (pt) | formulações para tratamento ocular | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
NZ607103A (en) | A water-in-oil type emulsion for treating a disease of the eye | |
MY199237A (en) | Methods of treating ocular conditions | |
WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
BR112019007539A2 (pt) | formulações para liberação entérica de agentes terapêuticos | |
BR112016008060A8 (pt) | composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo | |
MX2019014201A (es) | Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas. | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
JP2015522601A5 (pt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2015, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2591 DE 01/09/2020 QUANTO AO TITULO. |